Raziel Therapeutics
Injectable Drug for Treatment of Obesity
Company Overview
Snapshot
Founded in August 2012, Raziel Therapeutics operates with 1–10 employees. The company has raised $27.1M across 5 funding rounds from 9 investors. In October 2025, Peregrine Ventures participated in a funding round for Raziel Therapeutics.
Business overview
Raziel Therapeutics is a clinical-stage pharmaceutical company focused on developing a proprietary injectable drug for targeted fat reduction. The company's core technology involves a new chemical entity, RZL-012, designed to convert white adipose tissue into brown adipose tissue after a single injection, aiming to treat overweight and obese individuals. RZL-012 is currently in preclinical development and works by triggering fat-cell death, which is then replaced by fibrotic tissue, leading to sustained fat tissue shrinkage. Raziel Therapeutics operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, addressing conditions like obesity and Dercum's disease.
Strategic signal
In July 2025, Raziel Therapeutics announced a strategic collaboration with 365mc, a leading South Korean medical institution specializing in fat reduction treatments. This partnership aims to accelerate the development of RZL-012 in South Korea, signaling a significant move towards international market expansion and validation of its drug candidate in a key Asian market.
Log in to access full profile ›Company Intelligence Q&A
- What is Raziel Therapeutics' primary drug candidate?
- Raziel Therapeutics' primary drug candidate is RZL-012, an injectable drug currently in preclinical development for targeted fat reduction.
- When did Raziel Therapeutics receive FDA approval for RZL-012 as an orphan drug?
- In November 2019, Raziel Therapeutics received FDA approval to develop RZL-012 as an orphan drug for Dercum's disease.
- Which investors participated in Raziel Therapeutics' December 2019 funding round?
- In December 2019, Raziel Therapeutics secured funding from lead investor Pontifax.
- What strategic collaboration did Raziel Therapeutics announce in July 2025?
- In July 2025, Raziel Therapeutics announced a strategic collaboration with 365mc, a South Korean medical institution, to accelerate the development of RZL-012 in South Korea.
- Which investor participated in Raziel Therapeutics' October 2025 funding round?
- In October 2025, Peregrine Ventures participated in a funding round for Raziel Therapeutics.